Enhancing Innate Anti-Viral Resistance Through A Community-Based Intervention - Generation Xchange (GenX)

University of California, Los Angeles (UCLA)

Status: Invitation-only

Conditions: Virus Infection, RNA

Treatments: Behavioral: GenX intergenerational mentoring program

Study type: Interventional

Funder types: Other; NIH

Identifiers

NCT05534425

R01AG073053 (U.S. NIH Grant/Contract)

21-001388

Details and patient eligibility

About

This randomized controlled trial will test whether a recently developed community-based intergenerational mentoring program known as Generation Xchange (GenX) can enhance antiviral resistance in older African-American women and men in a low-SES urban community. Additional studies will identify the biological processes that promote resistance to respiratory virus infections and viral disease in older African-American women and men.

Full description

This randomized controlled intervention trial (planned n=160) will test whether participation in the Generation Xchange (GenX) intergenerational mentoring program can reduces vulnerability to respiratory virus infections (COVID, influenzas, colds), increase antiviral immune activity (Type I interferon responses), and reduce inflammatory immune activity in older African-American women and men living in a socioeconomically disadvantaged urban community. Blood samples will also be collected to determine which biological factors are most important in protecting older African-Americans from respiratory virus infection, and which of those factors is affected by the GenX intervention.

Enrollment: 160 estimated patients

Sex: All

Ages: 50+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Participating in the GenX intergenerational mentoring program
• All GenX mentors > 50 years of age are eligible to participate in this research
• GenX program participation requires:
• Reside in neighborhood of GenX schools (South-Central Los Angeles)
• Pass basic literacy and cognitive function tests

Exclusion criteria

• Any health condition that would put participant at risk by enrollment/participation

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Single Blind

---

160 participants in 2 patient groups

Immediate GenX

Experimental group

Description:

Participants immediately commence GenX program activity (intergenerational mentoring)

Treatment:

Behavioral: GenX intergenerational mentoring program

Delayed GenX

Active Comparator group

Description:

Participants engage in parallel training/educational activities, and subsequently commence GenX program activity after 3 months

Treatment:

Behavioral: GenX intergenerational mentoring program